The economic burden of complications during percutaneous coronary intervention

Quality and Safety in Health Care

Volumn 16, Issue 2, 2007, Pages 154-159

  Jacobson, Kurt M ^b   Long, Kirsten Hall ^b   McMurtry, Erin K ^b   Naessens, James M ^b   Rihal, Charanjit S ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; TIROFIBAN;

ADULT; AGED; ANEURYSM; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART DISEASE; HEART INFARCTION; HEMATOMA; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PEROPERATIVE COMPLICATION; STROKE; SURGICAL MORTALITY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; LENGTH OF STAY; LINEAR MODELS; MALE; MINNESOTA; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RISK FACTORS;

EID: 34247148055     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2006.019331     Document Type: Article

References (43)

1. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas, Texas: American Heart Association, 2006, Available at http://www.americanheart.org/presenter.jhtml?identifier=1928 (accessed 13 February 2006).
2. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
3. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341:319-27.
4. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
5. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without obciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
6. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000;356:2037-44.
7. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001;285:2468-73.
8. Morice MC, Serruys PW, Sousa JE, et al. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. N Engl J M 2002;346:1773-1780.
9. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
10. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
11. Kong DF, Eisenstein EL, Sketch MH, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J 2004;147:449-456.
12. Eagle KA, Knight BP, Moscucci M, et al. Competitive bidding for interventional cardiology supplies: lessons learned during round 2. Am J Manag Care 2002;8:384-388.
13. Moscucci M, Muller DW, Watts CM, et al. Reducing costs and improving outcomes of percutaneous coronary interventions. Am J Manag Care 2003;9:365-372.
14. Ferguson TB Jr, Peterson ED, Coombs LP, et al. Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. JAMA 2003;290:49-56.
15. Cheah J. Clinical pathways - an evaluation of its impact on the quality of care in an acute care general hospital in Singapore. Singapore Med J 2000;41:335-346.
16. Malenka DJ, O'Connor GT. The Northern New England Cardiovascular Disease Study Group: a regional collaborative effort for continuous quality improvement in cardiovascular disease. Jt Comm J Qual Improv 1998;24:594-600.
17. Hashimoto H, Bohmer RM, Harrell LC, et al. Continuous quality improvement decreases length of stay and adverse events: a case study in an interventional cardiology program. Am J Manag Care 1997;3:1141-1150.
18. Eagle KA, Moscucci M, Kline-Rogers E, et al. Evaluating and improving the delivery of heart care: the University of Michigan experience. Am J Manag Care 1998;4:1300-1309.
19. Senter DR, Nathan S, Gupta A, et al. Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol 2006;18:49-53.
20. Cohen DJ, Lineoff AM, Lovelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa Inhibition for Percutaneous Coronary Intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-1800.
21. Holmes DR Jr, Vlietstra RE. Percutaneous transluminal coronary angioplasty: current status and future trends. Mayo Clin Proc 1986;61:865-876.
22. Hasdai D, Garratt KN, Grill DE, et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997;336:755-761.
23. Cohen DJ, Breall JA, Ho K, et al. Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting, and bypass surgery. J Am Coll Cardiol 1993;22:1052-1059.
24. The MEDSTAT Group, Inc. Medstat Disease Staging™ Software Version 5.22. Reference guide. 2004. Available online at, http://www.hcup-us. ahrq.gov/db/nation/nis/Disease%20Staging%20V5.22%20Reference%20Guide.pdf, Accessed November 17, 2006.
25. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res & Policy 2004;9:197-204.
26. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494.
27. Manca A, Palmer S. Handling missing data in patient-level cost-effectiveness analysis alongside randomized clinical trials. Appl Health Econ Health Policy 2005;4:65-75.
28. Weintraub WS, Mahoney EM, Ghazzal ZMB, et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardio 2001;88:497-503.
29. Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol 2000;36:723-730.
30. Cote AV, Berger PB, Holmes DR Jr, et al. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 2001;76:890-896.
31. Rabah M, Mason D, Muller DW, et al. Heparin after percutaneous intervention (HAPI): A prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. JAMA 1999;34:461-467.
32. Lauer MA, Karweit JA, Cascade EF, et al. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 2002;89:924-929.
33. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994;24:1214-1219.
34. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIB/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-862.
35. Nikolsky E, Sadeghi M, Effron MB, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2005;96:474-481.
36. Kugelmass AD, Cohen DJ, Brown PB, et al. Hospital resources consumed in treating complications associated with percutaneous coronary interventions. Am J Cardiol 2006;97:322-327.
37. Aronow HD, Peyser PA, Eagle KA, et al. Predictors of length of stay after coronary stenting. Am Heart J 2001;142:799-805.
38. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors and prognostic implications of bleeding and blood transfusion following percutaneous interventions. Am J Cardiol 2003;92:930- 935.
39. Cohen DJ, Becker ER, Culler SD, et al. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories. Am J Cardiol 2000;86:595-601.
40. Singh M, Lennon RJ, Holmes DR, et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol 2002;40:387-393.
41. Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention: A sub analysis of the REPLACE-2 trial. Am J Cardiol 2005;95:581-585.
42. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006;367:579-588.
43. Cooper CJ, El-Shiekh RA, Cohen DJ, et al. Effect of transradial access on quality of life and cost of cardiac catheterization: A randomized comparison. Am Heart J 1999;138:430-436.